Schizoaffective Disorder
📧 Sign up to get email alerts when something new happens for Schizoaffective Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2013-01-16Clinical Trial Update: Adherence and Quality of Life in People With Schizophrenia and Schizoaffective Disorder
A clinical trial update examining adherence and quality of life in individuals with schizophrenia and schizoaffective disorder.
-
CLINICAL_TRIALS trial_result · 2012-12-19Clinical Trial Update: Comparison of Antipsychotics for Metabolic Problems in Schizophrenia or Schizoaffective Disorder [Phase 4]
NIMH-sponsored Phase 4 clinical trial comparing antipsychotics for metabolic problems in schizophrenia and schizoaffective disorder with res…
-
CLINICAL_TRIALS trial_result · 2012-12-17Clinical Trial Update: A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder [Phase 3]
Phase 3 study evaluating switching to lurasidone for schizophrenia or schizoaffective disorder; results were posted after completion in 2012…
-
CLINICAL_TRIALS trial_result · 2012-12-13Clinical Trial Update: Recovery From Psychosis in Schizophrenia - The Impact of Cognitive-Behavioral Therapy [NA]
This entry reports the completion of a clinical trial evaluating the impact of cognitive-behavioral therapy on recovery from psychosis in in…
-
CLINICAL_TRIALS trial_result · 2012-12-12Clinical Trial Update: Efficacy Study of Panax Ginseng to Boost Antipsychotics Effects in Schizophrenia [Phase 1, Phase 2]
A completed Phase 1/Phase 2 study assessed whether Panax ginseng can enhance the efficacy of antipsychotics in schizophrenia and schizoaffec…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2012-12-03Clinical Trial Update: The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning [Phase 3]
Phase 3 trial evaluating the impact of galantamine hydrobromide as an adjunct to electroconvulsive therapy on mood and cognitive outcomes in…
-
CLINICAL_TRIALS trial_result · 2012-11-29Clinical Trial Update: Olanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic Subjects [Phase 2]
Phase 2 clinical trial evaluating olanzapine in combination with zonisamide sustained-release to prevent weight gain in patients with schizo…
-
FDA approval · 2012-11-27FDA Approved: RISPERIDONE — Supplemental Application (Chartwell RX, LLC)
FDA approved Chartwell RX, LLC's generic risperidone through an ANDA, authorizing the generic product for the same indications as the brand.
-
CLINICAL_TRIALS trial_result · 2012-11-19Clinical Trial Update: Improving Diabetes Risk Factors in Persons With Schizophrenia or Bipolar Disorder by Switching to Ziprasidone [NA]
A completed clinical trial evaluated diabetes risk factors in people with schizophrenia or bipolar disorder after switching to ziprasidone; …
-
CLINICAL_TRIALS research · 2012-10-25Clinical Trial Update: N-methyl-D-aspartic Acid (NMDA) and Cognitive Remediation in Schizophrenia [Phase 2]
An update on a Phase 2 trial investigating N-methyl-D-aspartic acid (NMDA) with cognitive remediation for schizophrenia and schizoaffective …
-
CLINICAL_TRIALS research · 2012-09-19Clinical Trial Update: Decision Aid to Facilitate Shared Decision Making During Treatment in Schizophrenia [NA]
This clinical trial update reports on a decision aid designed to facilitate shared decision making during treatment for schizophrenia and sc…
-
CLINICAL_TRIALS research · 2012-09-18Clinical Trial Update: The Consta Club: A Demonstration Project for Setting up a Consta Club in a Community Mental Health Center [NA]
A demonstration project to set up a Consta Club in a community mental health center. The study status is completed.
-
CLINICAL_TRIALS trial_result · 2012-09-13Clinical Trial Update: Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia [Phase 4]
Phase 4 trial evaluating ramelteon as an adjunct therapy in non-diabetic patients with schizophrenia and related disorders; results have bee…
-
FDA approval · 2012-08-29FDA Approved: INVEGA SUSTENNA — Supplemental Application (Janssen Pharmaceuticals, Inc.)
FDA approves a supplemental application for INVEGA SUSTENNA (paliperidone palmitate) submitted by Janssen Pharmaceuticals, extending/adjusti…
-
CLINICAL_TRIALS trial_result · 2012-08-16Clinical Trial Update: A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents [Phase 3]
A Phase 3 clinical trial evaluated lurasidone for the treatment of schizophrenia or schizoaffective disorder in patients switched from other…
-
CLINICAL_TRIALS trial_result · 2012-08-06Clinical Trial Update: A Comparison of Risperidone With Haloperidol in Patients With Schizophrenia and Schizoaffective Disorder [Phase 4]
This update reports the completion of a Phase 4 clinical trial comparing risperidone with haloperidol in patients with schizophrenia and sch…
-
CLINICAL_TRIALS trial_result · 2012-07-30Clinical Trial Update: Schizophrenic Patients in Integrated Care [Phase 4]
Phase 4 clinical trial sponsored by AstraZeneca evaluating schizophrenia-related conditions was terminated, with results posted in 2012.
-
CLINICAL_TRIALS trial_result · 2012-07-12Clinical Trial Update: Impact of Genetic Counseling for Individuals With Mental Illness [Phase 3]
This Phase 3 trial evaluating the impact of genetic counseling in individuals with schizophrenia, bipolar disorder, and schizoaffective diso…
-
CLINICAL_TRIALS trial_result · 2012-07-09Clinical Trial Update: 24-Hour Time Course of Striatal Dopamine D2 Receptor Occupancy of Ziprasidone: A PET Study [NA]
This completed PET imaging study characterizes the 24-hour time course of striatal D2 receptor occupancy by ziprasidone in schizophrenia and…
-
CLINICAL_TRIALS trial_result · 2012-07-06Clinical Trial Update: Tetrabenazine for Partial Responders [NA]
A completed clinical trial evaluated tetrabenazine as a treatment option for partial responders with schizophrenia or schizoaffective disord…
-
CLINICAL_TRIALS trial_result · 2012-06-21Clinical Trial Update: Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia [Phase 1]
Phase 1 study evaluating safety, tolerability, and pharmacokinetics of EVP-6124 (encenicline) in schizophrenia and schizoaffective disorder,…
-
CLINICAL_TRIALS trial_result · 2012-06-18Clinical Trial Update: D-Serine for Enhancing Cognitive Retraining for the Treatment of Schizophrenia [Phase 3]
Phase 3 trial evaluating D-Serine as an adjunct to cognitive retraining for schizophrenia has completed.
-
CLINICAL_TRIALS trial_result · 2012-05-17Clinical Trial Update: Evaluation of the Strategies of Switching Schizophrenia Patients to Aripiprazole From Other Antipsychotic Agents [Phase 4]
Phase 4 clinical trial evaluating strategies for switching schizophrenia patients to aripiprazole from other antipsychotics; status complete…
-
CLINICAL_TRIALS trial_result · 2012-05-08Clinical Trial Update: Allopurinol in Schizophrenia: A Randomized Trial Administering Allopurinol vs Placebo as add-on Antipsychotics in Patients With Schizophrenia [Phase 4]
Phase 4 randomized trial evaluating add-on allopurinol versus placebo in patients with schizophrenia (including schizoaffective disorder); t…
-
CLINICAL_TRIALS trial_result · 2012-05-03Clinical Trial Update: Cognitive Therapy for Negative Symptoms and Functioning [Phase 2]
Phase 2 study evaluating cognitive therapy to reduce negative symptoms and improve functioning in schizophrenia and schizoaffective disorder…